In a blog post today, AHA Executive Vice President Tom Nickels takes issue with a recent Axios article comparing hospital prices to drug prices. “Comparing hospital prices to drug prices is absurd,” Nickels writes. “And although the article claims to be about prices, the chart actually shows National Health Expenditure spending numbers, not prices. Despite that, hospital spending has grown at a slower rate than drug spending over the time period displayed in the chart. And as a percentage of the NHE, hospital care actually declined from 42.7% in 1980 to 34% in 2016, compared to retail prescription drug spending, which doubled as a share of total national health expenditures. … Hospital prices have also grown more slowly than drug prices, despite rising input costs. Hospital price growth as measured by the Producer Price Index, has remained under 2% for each of the last four years. Even before that, since 2008, hospital prices had an average annual growth rate of 2%. In comparison, the overall price of medical care had an average annual growth rate of 3%, while drug prices had a significantly higher average annual growth rate of 5.6% for that same time period.”

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
The AHA has released its 2026 Environmental Scan, a comprehensive resource designed to help hospitals and health systems navigate a rapidly evolving landscape…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…